Vaccination produces increased twine blood antibodies than COVID an infection
JAMA Community Open printed a brand new examine yesterday exhibiting increased twine blood COVID-19 antibodies in ladies who had been vaccinated in contrast with those that had been contaminated with COVID-19, suggesting vaccination produces greater than 10-fold increased antibody concentrations in unborn infants in comparison with pure infections.
The examine was based mostly on sufferers who gave delivery at Pennsylvania Hospital in Philadelphia between Aug 9, 2020, and Apr 25, 2021, a interval encompassing when preliminary mRNA vaccine collection grew to become obtainable, however earlier than the approval of booster doses. In complete, 585 pregnancies with twine blood serum samples had been recognized, together with 169 sufferers who had been vaccinated however by no means contaminated and 408 who had been contaminated however not vaccinated.
The researchers additionally detected IgG antibodies to SARS-CoV-2 within the twine blood from greater than 95% of newborns (557 of 585) within the examine.
These with maternal vaccination solely had considerably increased antibody ranges in comparison with the an infection group, however switch ratios, or how a lot the antibody ranges within the twine blood match the antibody ranges within the mom, had been decrease within the vaccinated group in contrast with the pure an infection group, (0.80 [95% confidence interval CI, 0.68-0.93] vs 1.06 [95% CI, 0.98-1.14]; P < .001).
The authors mentioned time to switch was most affected by time since vaccination, with 8 weeks or extra between vaccination and supply producing the best ranges.
“These findings can inform optimum COVID-19 vaccination technique throughout being pregnant,” mentioned senior writer Karen M. Puopolo MD, PhD, of the Kids’s Hospital of Philadelphia and Chief of the Part on New child Medication at Pennsylvania Hospital in a press launch. “Sufferers ought to plan to get vaccinated with ample time earlier than their due date, in order that they – and their infants – can profit from a sturdy immune response.”
Nov 9 JAMA Netw Open study
Nov 9 Kids’s Hospital of Philadelphia press release
Israeli examine reveals fourth Pfizer dose safety wanes by 6 months
Yesterday in a letter to the New England Journal of Medication, Israeli researchers reported an general vaccine effectiveness of a fourth Pfizer COVID vaccine dose of 41% within the first 6 months, however they mentioned safety decreased from 52% throughout the first 5 weeks after vaccination to no safety at 15 to 26 weeks.
The findings come from an ongoing potential cohort examine of healthcare staff vaccinated in Israel. Vaccine effectiveness was decided by evaluating an infection charges following the fourth dose (days 7 by means of 35, days 36 by means of 102, or days 103 by means of 181 after receipt of the fourth dose) to infections in those that obtained a 3rd dose solely, a minimum of 4 months earlier.
“Antibody response peaked at roughly 4 weeks, waned to ranges seen earlier than the fourth dose by 13 weeks, and stabilized thereafter,” the authors mentioned.
The safety supplied by a fourth dose was not as sturdy because the safety supplied by a 3rd dose, the authors mentioned, with no substantial further effectiveness over a 3rd dose at 15 to 26 weeks after vaccination.
“These outcomes counsel that the fourth dose, and presumably future boosters, ought to be timed properly to coincide with illness waves or to be obtainable seasonally, just like the influenza vaccine. Whether or not multivalent booster doses will end in longer sturdiness stays to be seen,” the authors concluded.
Nov 9 N Engl J Med study